Skip to main content
MJFF Feed

MJFF Awardee to Study Drug with Potential to Treat Dyskinesia

MJFF Awardee to Study Drug with Potential to Treat Dyskinesia

California-based biotech Avanir Pharmaceuticals today announced funding from The Michael J. Fox Foundation for a clinical study of a drug designed to treat dyskinesia in people with Parkinson’s.

The study will test the safety and efficacy of their drug called AVP-923 (dextromethorphan hydrobromide and quinidine sulfate), and will be conducted at three centers across the United States and Canada. According to Avanir, the trial will be a proof-of-concept study designed to compare their drug with a placebo treatment.

AVP-923 is also currently in development to treat multiple sclerosis.

 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.